Allarity Therapeutics, Inc. Common Stock
ALLRAllarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment. The company specializes in identifying targeted therapies based on tumor biology and genetic profiles to improve patient outcomes. Previously known as Oncothyreon Inc., Allarity aims to advance its pipeline through research and partnerships in oncology.
Company News
Over 25 pharmaceutical companies are actively developing 30+ PARP inhibitor drugs in clinical trials, with major players including AstraZeneca, Gilead Sciences, and Nerviano Medical Sciences advancing promising candidates like Saruparib and NMS-293. The pipeline shows robust activity across multiple cancer indications including breast cancer, pro...
Allarity Therapeutics announced that the US Patent and Trademark Office has issued a Notice of Allowance for its stenoparib DRP® companion diagnostic patent application. The patent, expected to be formally granted within three months, would provide exclusivity for stenoparib when used with the DRP test at least through 2039. The allowed claims c...
Allarity Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital to fund Phase 2 ovarian cancer trial completion and advance stenoparib toward FDA approval and commercialization. The financing extends the company's cash runway into mid-2028 and supports preparation for pivotal development and regulatory meetings.
Allarity Therapeutics announced that enrollment is now open for a Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for treating recurrent small cell lung cancer. The trial is conducted in collaboration with the U.S. Department of Veterans Affairs and fully funded through the VA's Special Emphasis Panel on Precision...
Allarity Therapeutics reported significant progress with stenoparib, receiving FDA Fast Track designation for advanced ovarian cancer and presenting clinical trial data showing median overall survival exceeding 25 months for patients receiving the drug twice daily.
